Develops immune globulin products for immunodeficient patients.
Jun 2026Revenue $512M/yrExpenses $288M/yr
Reached break-even Sep 2023
Figures by year
When did Adma Biologics become profitable?
Its revenue passed its expenses in Sep 2023. In the 12 months to Jun 2026, revenue was $512M and expenses $288M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $510M | $319M | $191M |
| Dec 2024 | $426M | $287M | $139M |
| Dec 2023 | $258M | $237M | $21.6M |
| Dec 2022 | $154M | $193M | −$39.4M |
| Dec 2021 | $80.9M | $139M | −$58.4M |
| Dec 2020 | $42.2M | $107M | −$64.9M |
| Dec 2019 | $29.3M | $70.8M | −$41.4M |
| Dec 2018 | $17.0M | $77.3M | −$60.3M |
| Dec 2017 | $22.8M | $62.1M | −$39.3M |
| Dec 2016 | $10.7M | $28.0M | −$17.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.